People
Joint expertise to help tackle potential problems ranging from disease outbreaks to bioterrorism
Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.
It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company named a Genentech veteran to helm its oncology programs.
Theranos fit in with the opaque culture of Silicon Valley, which allowed it to thrive and amass a fortune without delivering anything, book argues.
CellGeni is pleased to announce the appointment of Dr. Udo Nirenberg as Vice President of Quality Management and member of the management team.
Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Andrew Wright has been appointed as Financial Controller & Company Secretary, a non-Board position, and that Lawrence Pemble, Chief Operating Officer, will step down from the Board, both with immediate effect.
MMS Holdings Inc. (MMS) - an award-winning, data-focused CRO - announced that one of its leader’s in programming and data sciences, Chris Hurley, has been asked and has accepted a second three-year term as Americas Director of PhUSE - an independent, global organization for more than 8,000 data managers, biostatisticians, clinical programmers, and eClinical IT professionals.
Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
PRESS RELEASES